These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 11566042)

  • 21. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic basis for selective inhibition of cyclo-oxygenases.
    Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
    Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract]   [Full Text] [Related]  

  • 24. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
    J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COX-2 inhibitors: no pain, no heart gain?
    Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
    Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
    J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E; Mejza F; Cmiel A; Szczeklik A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
    Whelton A
    J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.